1. SAT0192 Post-hoc analysis to assess effect of belimumab in patients on mycophenolate mofetil with renal manifestations at baseline. (23rd January 2014) Authors: Houssiau, F.; Dooley, M.A.; Aranow, C.; D'Cruz, D.; Askanase, A.; Roth, D.A.; Cooper, S.; Zhong, Z.J.; Freimuth, W.; Ginzler, E.M. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 536 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0197 Baseline laboratory characteristics from the combined placebo groups in the bliss trials are predictive of severe flare at 24 weeks. (23rd January 2014) Authors: Petri, M.; van Vollenhoven, R.F.; Levy, R.A.; Navarra, S.; Cervera, R.; Zhong, Z.J.; Freimuth, W.; Buyon, J. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 538 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0204 Predictors for SLE flares: Baseline disease activity and demographic characteristics from the bliss trials' combined placebo groups. (23rd January 2014) Authors: van Vollenhoven, R.F.; Petri, M.; Levy, R.A.; Navarra, S.; Buyon, J.; Zhong, Z.J.; Freimuth, W.; Cervera, R. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 540 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗